Genetic evidence implicates the loss of bone morphogenetic protein type II receptor (BMPR-II) signaling in the endothelium as an initiating factor in pulmonary arterial hypertension (PAH). However, selective targeting of this signaling pathway using BMP ligands has not yet been explored as a therapeutic strategy. Here, we identify BMP9 as the preferred ligand for preventing apoptosis and enhancing monolayer integrity in both pulmonary arterial endothelial cells and blood outgrowth endothelial cells from subjects with PAH who bear mutations in the gene encoding BMPR-II, BMPR2. Mice bearing a heterozygous knock-in allele of a human BMPR2 mutation, R899X, which we generated as an animal model of PAH caused by BMPR-II deficiency, spontaneously developed PAH. Administration of BMP9 reversed established PAH in these mice, as well as in two other experimental PAH models, in which PAH develops in response to either monocrotaline or VEGF receptor inhibition combined with chronic hypoxia. These results demonstrate the promise of direct enhancement of endothelial BMP signaling as a new therapeutic strategy for PAH. npg
Heritable and idiopathic PAH are characterized by narrowing and obliteration of precapillary pulmonary arteries secondary to proliferation and apoptosis resistance of endothelial cells, smooth muscle cells and fibroblasts 1 . The resulting increase in pulmonary vascular resistance causes severe elevation of pulmonary artery pressure leading to right ventricular hypertrophy and ultimately death from right heart failure 2 . The identification of heterozygous germline mutations in BMPR2 provided major insights into the pathobiology of heritable PAH 3, 4 . Subsequent studies identified BMPR2 mutations in 15-40% of idiopathic cases of PAH 5 and found that reduced BMPR-II expression is a feature of nongenetic forms of PAH in humans 6 and animal models 7 .
Genetic evidence strongly implicates the endothelial cell as the key initiating cell type in PAH. Previous studies showed that conditional deletion of Bmpr2 in the endothelium is sufficient to induce PAH in a proportion of mice 8 and that rescue of endothelial BMPR-II expression reverses experimental pulmonary hypertension [9] [10] [11] . In addition, mutations in two genes whose products, the type I receptor ALK-1 (ref. 12 ) and the type I receptor accessory protein endoglin 13 , are almost exclusively expressed on the endothelium are found in individuals with PAH. Despite this evidence, the precise nature of endothelial dysfunction in the pathobiology of PAH, and how BMP signaling is involved in this dysfunction, remain uncertain. Although established PAH is characterized by the excessive clonal proliferation of pulmonary endothelial cells as a component of obstructive cellular lesions 14 , the initiation of disease pathology has been linked to a paradoxical increase in endothelial cell apoptosis [15] [16] [17] . Additional studies have identified a role for endothelial BMPR-II loss in the exacerbation of vascular permeability and altered translocation of leukocytes across the vascular wall [18] [19] [20] .
While in vitro studies using pulmonary artery smooth muscle cells (PASMCs) have demonstrated that treatment with increasing concentrations of BMP ligand overcomes the loss of growth suppression associated with mutations affecting the BMP signaling pathway 21 , no study to date has therapeutically delivered BMP ligand in vivo to provide proof of concept for such an approach in the treatment of PAH. The complexity of the BMP receptor family-comprised of four type-II receptors, five type-I receptors and over 20 BMP ligands 22 -may account for the absence of such studies. Identifying an appropriate ligand to selectively target the pulmonary endothelium presents a significant challenge. Recently, BMPR-II was found to form a signaling complex with ALK-1 and signal specifically in response to BMP9 and BMP10 in microvascular endothelial cells 23 . Unlike other BMPs, BMP9 circulates at measurable concentrations in serum and is thought to act as a vascular quiescence factor, blocking angiogenesis in vitro 24 and in vivo 25 . These features suggest that BMP9 may be able to therapeutically rescue the dysfunctional pulmonary endothelium.
Here we examined the therapeutic administration of BMP9 to prevent and reverse established PAH by selectively enhancing endothelial BMPR-II signaling. In cultured endothelial cells, we found that BMP9 prevents apoptosis, decreases angiogenic behavior and promotes monolayer integrity. As a new animal model of PAH, we generated mice bearing a knock-in allele of a common human disease-causing mutation, R899X, encoding a stop codon in place of an arginine codon at the endogenous Bmpr2 locus. Unlike previous mouse models of Bmpr2 haploinsufficiency 26, 27 , mice heterozygous for this knock-in allele (Bmpr2 +/R899X ) spontaneously developed pulmonary hypertension. Therapeutic delivery of BMP9 effectively prevented and reversed established pulmonary hypertension in these mice as well as in the monocrotaline and Sugen-hypoxia rat models of PAH. Together, these studies underscore a role for BMP9 as a vascular stability and quiescence factor and provide a translational framework for the delivery of this BMP ligand as a treatment strategy for PAH.
RESULTS

BMP9 elicits endothelial-selective transcriptional regulation
We sought to identify a BMP ligand for therapeutic delivery that would selectively and efficiently enhance canonical BMP signaling in the endothelium while minimizing the potential for deleterious off-target effects, such as the calcification of soft tissue 28 . As an initial screen, we stimulated human pulmonary arterial endothelial cells (PAECs) with BMP9, BMP2 or BMP6 and assessed changes in gene npg transcription by microarray analysis. Unlike BMP2 and BMP6, which induced negligible gene expression, BMP9 induced the differential regulation of 1,883 genes (adjusted P value < 0.05), including several key components of canonical BMP signaling such as ID1, ID2 and BMPR2 (Fig. 1a-c) . Generally applicable gene-set enrichment (GAGE) analysis for common signaling pathways and cellular processes revealed TGF-β signaling as the only pathway to be significantly (P = 0.0012) upregulated by BMP9. However, BMP9 also downregulated other pathways, including apoptotic cell signaling ( Fig. 1d and Supplementary Fig. 1 ). Signaling pathway impact analysis (SPIA) of common signaling pathways confirmed the TGF-β pathway as the only one to be enhanced in response to BMP9 treatment, supporting a central role for the canonical Smad pathway in the actions of BMP9 ( Fig. 1e) . We obtained similar results using blood outgrowth endothelial cells (BOECs) from healthy subjects, which, like PAECs, responded almost exclusively to BMP9 stimulation ( Supplementary  Fig. 2 ). Analysis of BMP9-induced gene expression for specific members of the TGF-β pathway revealed an enhancement of canonical downstream targets of BMP signaling, whereas expression levels of TGF-β1 downstream targets, including PAI-1, Myc and CTGF, were unchanged ( Supplementary Fig. 3a ). Of note, BMP9 did not alter the expression of a selected group of endothelial-derived paracrine factors and typical PASMC mitogens, including members of the PDGF and FGF families of cytokines ( Supplementary Fig. 3b ).
Validation of BMP responsiveness in PAECs by immunoblotting confirmed robust phosphorylation of Smads 1, 5 and 8, and induction of gene expression of ID1 and ID3 in response to BMP9 at concentrations as low as 0.1 ng/ml. In contrast, other BMPs were much less effective over the range of doses tested ( Fig. 1f and Supplementary Fig. 4 ). As a further measure of endothelial selectivity, PASMCs displayed a modest response to BMP9 when compared to an equivalent dose range of other BMPs (Supplementary Fig. 4a,b) . We employed a range of additional cell lines to confirm the selectivity of BMP9 over other BMPs in stimulating signaling in endothelial cells ( Supplementary  Fig. 4b ). As a further measure of the endothelial selectivity of BMP9 in the pulmonary circulation, we assessed phosphorylation of Smads 1 and 5 in freshly isolated rat pulmonary arteries treated with BMP9 ex vivo. BMP9 induced phospho-Smad immunostaining exclusively in the endothelium, with no measurable signal in the underlying smooth muscle (Supplementary Fig. 4c ).
We next validated the ability of BMP9 to induce BMPR2 gene expression in PAECs, as identified in the microarray study, by immunoblotting and qPCR ( Fig. 1f,g) . siRNA knockdown of Smad1, with or without Smad5 knockdown, eliminated the capacity of BMP9 to enhance BMPR2 expression ( Supplementary Fig. 5a-d) , supporting the importance of canonical Smad signaling to this process. Next, we identified a putative Smad-binding site in the BMPR2 promoter ( Supplementary Fig. 5e ) and used chromatin immunoprecipitation (f) Cytometric quantification of apoptosis by staining for annexin-V and PI in PAECs treated with DH1 alone, siBMPR2 or siCP and cultured without or with BMP9 pretreatment and apoptotic stimulus (n = 6 for DH1 and siBMPR2; n = 5 for siCP; ANOVA for each siRNA group, Tukey's post hoc test). (g) Representative immunoblots and densitometric analysis of cleaved caspase-3 in PAECs following siRNA transfection without or with BMP9 pretreatment and apoptotic stimulus. (n = 3). All blots were reprobed for α-tubulin as a loading control. One-way ANOVA, Tukey's post hoc test used in a,b,d,f and g. ***P < 0.001, **P < 0.01, *P < 0.05. Error bars are mean ± s.e.m. npg (ChIP) in human microvascular endothelial cells (HMEC-1) to show that phospho-Smads 1 and 5 and Smad4 bound to this region ( Fig. 1h) . Moreover, this binding was lost following siRNA knockdown of Smad1 and was enhanced in response to treatment with BMP9 ( Fig. 1h) . HMEC-1 cells transfected with a luciferase reporter construct containing a 5-kb segment of the BMPR2 promoter including this binding region exhibited enhanced basal luciferase activity compared to those transfected with a control vector without the BMPR2 promoter segment ( Fig. 1i) . Luciferase activity of the intact construct was elevated in response to BMP9 treatment, and mutation of the putative Smadbinding region reduced both baseline luciferase activity and BMP9 regulation of the promoter (Fig. 1i ). We did not observe a similar enhancement of BMPR2 expression in PASMCs in response to treatment with BMP9, BMP2 or BMP6 (Supplementary Fig. 5f ).
BMP9 prevents endothelial cell apoptosis and permeability
As reported previously 29 , PAECs stimulated with tumor necrosis factor α (TNFα) in the presence of cycloheximide, to inhibit the anti-apoptotic arm of the TNFα pathway, exhibited increased levels of apoptosis and elevated JNK phosphorylation ( Fig. 2a) . Pretreatment of PAECs with BMP9 prevented TNFα-induced JNK phosphorylation and blocked the induction of apoptosis, as demonstrated by immunoblotting for cleaved caspase-3 ( Fig. 2b) and by flow cytometry for early apoptotic, annexin-V + propidium iodide (PI) − cells ( Fig. 2c,d) . Since BMP9 signals via a receptor complex containing the type I receptor ALK-1 in conjunction with either of two type II receptors, BMPR-II or ActR-II (ref. 30) , we determined whether the anti-apoptotic effects of BMP9 were indeed BMPR-II dependent. siRNA knockdown of BMPR2 ( Fig. 2e ) eliminated the ability of BMP9 to prevent apoptosis ( Fig. 2f,g) . Notably, siRNA knockdown of SMAD1 and SMAD5 also partially blocked the anti-apoptotic effect of BMP9, indicating the importance of canonical Smad signaling in this process ( Supplementary Fig. 6 ).
BOECs from healthy controls and individuals with different PAH-associated mutations in BMPR2 were used as a surrogate for PAECs to determine the efficacy of BMP9 therapy in the context of BMPR2 mutations. Although mutation-bearing BOECs displayed an increased susceptibility to TNFα-induced apoptosis compared to cells isolated from healthy control subjects ( Fig. 3a) , BMP9 blocked JNK phosphorylation ( Fig. 3b ) and apoptosis in both control and mutation-bearing BOECs (Fig. 3a,c) , supporting the benefit of this approach, even in the context of BMPR-II deficiency.
We also examined the effect of BMP9 on endothelial barrier integrity ( Fig. 3d-g) . Lipopolysaccharide (LPS) stimulation of control BOECs resulted in an increase in monolayer permeability, which was blocked by pretreatment with BMP9. BOECs with BMPR2 mutations demonstrated greater permeability in response to LPS compared to control BOECs. As with the TNFα-induced apoptotic response, heterozygous BMPR2 mutation did not prevent the ability of BMP9 to block LPS-induced monolayer permeability. BMP9 also reduced the basal permeability of unstimulated, mutation-bearing BOECs (Fig. 3f) . We observed similar results in PAECs in response to TNFα-or thrombininduced permeability (Supplementary Fig. 7a ). In response to all three stimuli, cell-cell junctions were impaired as assessed by vascular endothelial (VE)-cadherin staining, and these effects were blocked by BMP9 pretreatment ( Fig. 3g and Supplementary Fig. 7b ).
Bmpr2 +/R899X mice develop age-related pulmonary hypertension
To determine whether exogenous administration of BMP9 would be beneficial in a mouse model of PAH that mimics the genetics of human disease, we created a knock-in mouse strain which bears the human disease-associated R899X premature stop mutation in Fig. 8a ).
As reported for Bmpr2-null mice 31 , mice homozygous for the R899X mutation were nonviable. Heterozygous Bmpr2 +/R899X mice developed normally and displayed reduced BMPR-II protein ( Supplementary  Fig. 8b ) and mRNA ( Supplementary Fig. 8c) , consistent with the observation that the R899X mutation leads to mRNA degradation by nonsense-mediated mRNA decay (NMD) in humans 32 . We confirmed NMD of the R899X transcript in both mouse and human smooth muscle cells bearing the mutant allele ( Supplementary Fig. 8d-i) . Bmpr2 +/R899X mice exhibited normal right ventricular systolic pressure (RVSP) at 3 months of age ( Supplementary Fig. 9a ), but developed elevated RVSP by 6 months of age (Fig. 4a) . While this increase in RVSP was not accompanied by right ventricular hypertrophy (Fig. 4b) , 6-month-old Bmpr2 +/R899X mice did exhibit enhanced muscularization of peripheral pulmonary arteries in the lung (Fig. 4c,d) . Further characterization of left ventricular function demonstrated no significant differences in left ventricular end diastolic pressure or cardiac output between 6-month-old Bmpr2 +/R899X and wild-type (WT) control mice (Supplementary Table 1) . In contrast, 6-month-old Bmpr2 +/− mice did not exhibit elevated RVSP or right ventricular hypertrophy in our hands (Supplementary Fig. 9e,f) .
To examine the importance of canonical Smad signaling in this PAH model, we assessed the pulmonary vascular phenotype of mice heterozygous for a Smad1 knockout mutation 33 . Male Smad1 +/− mice did not exhibit raised RVSP or right ventricular hypertrophy at 3 or 6 months of age (Fig. 4e,f and Supplementary  Fig. 9b-d) . However, by 6 months of age, Bmpr2 +/R899X Smad1 +/− compound heterozygotes developed more severe elevations in RVSP than did mice heterozygous for R899X alone (Fig. 4e) . The more pronounced elevation in RVSP in Bmpr2 +/R899X Smad1 +/− mice was accompanied by right ventricular hypertrophy, which was not observed in Bmpr2 +/R899X mice (Fig. 4f) . Both Bmpr2 +/R899X and Bmpr2 +/R899X Smad1 +/− mice exhibited reduced levels of pulmonary BMPR-II protein and phospho-Smads 1 and 5 compared to WT littermate controls (Supplementary Fig. 9g-i) .
BMP9 reverses pulmonary hypertension in Bmpr2 +/R899X mice Treatment of 6-month-old Bmpr2 +/R899X mice with BMP9 (75 ng daily, intraperitoneal (i.p.) injection) for 4 weeks reversed all indices of PAH in this chronic disease model, returning RVSP to the level seen in WT mice (Fig. 4a) and reversing enhanced pulmonary arterial muscularization (Fig. 4c,d) . The dose selected was based (c) Quantitative assessment of pulmonary arterial muscularization in control rats or rats given MCT, followed by daily injections with saline or BMP9 in a prevention (days 0-21 post-MCT) or reversal (days 21-35 post-MCT) protocol. Non-, partially and fully muscularized arteries as a percentage of total alveolar wall and duct arteries were scored (n = 5 for each prevention group, n = 6 for each reversal group, n = 6 for control group); ANOVA for fully muscularized vessels. (d) Representative images of immunohistochemical staining for smooth muscle α-actin in lung sections from the rats described in c. Scale bars, 100 µm. on an initial, 7-d chronic dose-ranging study in rats that assessed effects on BMPR-II signaling in the lung (Supplementary Fig. 10a) ; we then extrapolated the weight-adjusted optimal dose to mice and validated the selected dose on BMPR-II signaling in mouse lungs (Supplementary Fig. 10b) .
We also used pulmonary endothelial cells from WT and Bmpr2 +/R899X mice to assess the capacity of BMP9 to enhance monolayer integrity in vitro. As with BMPR2 mutation-bearing BOECs, monolayers of Bmpr2 +/R899X endothelial cells displayed increased permeability both at baseline and following LPS stimulation. BMP9 pretreatment prevented LPS-induced permeability in both WT and Bmpr2 +/R899X endothelial cell monolayers ( Fig. 4g and Supplementary Fig. 10c,d) .
In vivo, Bmpr2 +/R899X and WT mice injected with LPS developed pulmonary vascular leak, as quantified by extravasation of Evans blue dye into lung tissue (Fig. 4h) . Bmpr2 +/R899X mice demonstrated increased dye extravasation compared to WT littermates, and treatment with BMP9 blocked dye extravasation to a similar degree in WT and Bmpr2 +/R899X mice (Fig. 4i) .
To further exclude the possibility that BMP9 acts through a direct effect on smooth muscle, we isolated PASMCs from WT and Bmpr2 +/R899X mice and observed similar rates of PASMC proliferation in response to serum in these cells (Supplementary Fig. 10e ). Additionally, BMP4, but not BMP9, reduced the proliferation of Bmpr2 +/R899X cells (Supplementary Fig. 10f ).
BMP9 reverses monocrotaline-induced pulmonary hypertension
We next assessed the efficacy of BMP9 treatment in the monocrotaline (MCT) rat model of PAH, a nongenetic model of disease in which reduction of BMPR-II expression is a central feature 7, 34 . BMP9 treatment for 21 d (600 ng/d, i.p.), commenced immediately following exposure to MCT (day 0), prevented elevation of RVSP, right ventricular hypertrophy and pulmonary arterial muscularization ( Fig. 5a-d) .
In a protocol in which BMP9 dosing was commenced 3 weeks after MCT exposure, a timepoint at which there is established PAH, 2 weeks of daily BMP9 treatment prevented the progression of PAH (Fig. 5c-f) .
In agreement with our previous reports, rats treated with MCT displayed reduced lung BMPR-II protein levels and impaired canonical BMP signaling (Supplementary Fig. 11a-d) . Treatment with BMP9 from days 0 to 21 restored BMPR-II levels and downstream signaling to near normal levels (Supplementary Fig. 11a-d ). npg Endothelial apoptosis is believed to be a primary factor in the initiation of PAH in animal models 16, 17 and human disease 15 . Staining of lung tissue for cleaved caspase-3 revealed enhanced pulmonary endothelial cell apoptosis at both 5 d and 3 weeks after MCT exposure (Fig. 5g,h) . Daily administration of BMP9 starting at day 0 prevented enhanced apoptosis at both time points (Fig. 5g,h) . Immunoblotting of whole lung lysates confirmed a reduction in cleaved caspase-3 levels in response to BMP9 at both 3 and 5 weeks after MCT exposure (Supplementary Fig. 11e ).
BMP9 reverses Sugen-hypoxia-induced pulmonary hypertension
We also examined the efficacy of BMP9 in a more severe PAH model, in which rats are exposed to chronic hypoxia in combination with the VEGF receptor blocker SU-5416 (ref. 17) (Fig. 6a) . Rats given SU-5416 and exposed to 3 weeks of hypoxia (10% O 2 ) and an additional 5 weeks of normoxia developed severe pulmonary hypertension and right ventricular hypertrophy (Fig. 6b,c) as well as extensive pulmonary arterial muscularization (Fig. 6d,e ). Daily BMP9 treatment (600 ng/d, i.p.) from weeks 8 to 11 resulted in a reversal of established disease-including a reduction in RVSP, right ventricular hypertrophy and vascular remodeling-as compared to control saline treatment ( Fig. 6b-e) .
Established disease was also characterized by angio-obliterative lesions (Fig. 6) and heightened endothelial cell apoptosis (Fig. 6g) , as well as by reduced phospho-Smad1 and Smad5 levels ( Supplementary Fig. 12a,b) ; all of these effects were reversed by BMP9 treatment. BMP9 treatment also decreased the levels of cleaved caspase-3 and PCNA, the latter a marker of cell proliferation, in whole lung lysates (Supplementary Fig. 12a) , consistent with the concept that BMP9 simultaneously prevents excessive endothelial cell apoptosis and pathological angiogenesis in this model. While BMP9 did not reverse elevated VEGFA gene expression in the lungs of Sugen-hypoxia rats, it did block VEGF-induced proliferation and tube formation of human PAECs in vitro (Supplementary Fig. 12c-i) . Assessment of left ventricular function revealed no significant changes in cardiac output in diseased animals given BMP9 compared to healthy controls (Supplementary Table 1) .
Similarly, mice given SU-5416 and exposed to 3 weeks of hypoxia (10% O 2 ) developed moderate to severe pulmonary hypertension and right ventricular hypertrophy accompanied by increased pulmonary arteriolar muscularization (Supplementary Fig. 13a-c) . Administration of BMP9 (75 ng/d, i.p.) throughout the period of treatment with SU-5416 and hypoxia resulted in normalization of right ventricular systolic pressure and right ventricular mass, and abrogated the muscularization of small arterioles. Treatment of mice with BMP9 did not result in heterotopic ossification at the sites of i.p. injection, based on X-ray and micro-CT analysis ( Supplementary  Fig. 13d) . Moreover, daily intramuscular injections of BMP9 (75 ng/d) to mice for 3 weeks failed to elicit intramuscular heterotopic ossification (Supplementary Fig. 13e ). 
npg
DISCUSSION
We report the use of a BMP ligand to enhance endothelial BMPR-II signaling and reverse established PAH in animal models of disease. This work also shows that mice heterozygous for a human diseasecausing mutation are susceptible to PAH, providing a new genetic model for this disease that, unlike previous models, closely mimics the genetics of human PAH.
One challenge associated with therapeutic application of BMPs for the treatment of PAH is the identification of a ligand that preferentially targets the pulmonary endothelium. Our microarray screen demonstrated the superiority of BMP9 as compared to other BMP ligands in stimulating pulmonary endothelial cells. Of note, we showed that BMP2, BMP4 and BMP6 possess a minimal ability to stimulate PAECs, which at first sight contrasts with previously published findings 26, 35, 36 . This discrepancy can largely be accounted for by differences in the concentrations of the BMPs used. The majority of papers describing a response of endothelial cells to BMP2, BMP4 or BMP6 used concentrations in excess of 10 ng/ml and often in the range of 50-200 ng/ml 15, 37 . Here we showed that the response of PAECs to BMP9 is already maximal at 1 ng/ml. Thus, while BMPs other than BMP9 have the ability to stimulate the endothelium, they do so only at high doses that would have no selectivity for the endothelium and would be likely to promote heterotopic ossification. In contrast, BMP9 allows for selective stimulation of canonical BMP signaling in pulmonary endothelial cells at concentrations that do not induce signaling in PASMCs and do not promote ossification. As ALK-1 is also expressed in hepatocytes, mesenchymal cells, chondrocytes and cardiomyocytes 38 , we cannot categorically exclude nonendothelial mechanisms of BMP9 treatment.
In vitro and in vivo studies demonstrated the ability of BMP9 to counteract enhanced apoptosis and decreased vascular stability, which are two critical aspects of PAH pathogenesis [15] [16] [17] [18] [19] [20] . The ability of BMP9 to prevent endothelial apoptosis in vitro is in agreement with previous studies that have reported anti-apoptotic effects of various BMP ligands 15, 35 . Despite the fact that BMP9 acts through BMPR-II, BMP9 provides protection in BMPR2 mutation-bearing BOECs, presumably due to signaling via the wild-type receptor. We also demonstrated that BMP9 inhibits endothelial permeability induced by a variety of agents relevant to PAH. Increased endothelial permeability is increasingly implicated in PAH pathobiology, and a recent study showed that loss of BMPR-II promotes Src kinase-dependent caveolar trafficking defects in heritable PAH 39 .
We also showed that BMP9 treatment increases BMPR-II levels in endothelial cells via a Smad-binding region in the BMPR2 promoter. In canonical BMP signaling, interactions of ligands with heterodimers of type I and type II receptors leads to phosphorylation of a restricted set of receptor-activated Smad proteins (Smads 1,5 and 8). However, non-Smad-mediated BMP signaling is involved in certain cellular responses. Despite the recent identification of rare mutations in SMAD1 and SMAD8 in individuals with PAH 40,41 , the relative contributions of Smad-and non-Smad-mediated signaling to the pathobiology of PAH remain uncertain. Our observation that compound heterozygous mice bearing loss-of-function mutations in both Bmpr2 and Smad1 develop more severe spontaneous PAH than do mice heterozygous for Bmpr2 alone supports a central role for the canonical BMPR-II-Smad signaling pathway in PAH. This concept is supported by a previous study showing that conditional deletion of Smad1 in endothelial cells in mice promotes the development of PAH 42 .
Although Bmpr2 +/R899X mice spontaneously developed elevated RVSP and enhanced pulmonary arteriolar muscularization by 6 months of age, these changes were not accompanied by right ventricular hypertrophy. One possible explanation is that the modest increase in RVSP in these mice (~35 mm Hg) was not sufficient to induce measurable right ventricular hypertrophy. This possibility is supported by the fact that Bmpr2 +/R899X Smad1 +/− mice, with a more severe elevation of RVSP, did develop right ventricular hypertrophy. Alternatively, a recent report using a pulmonary arterial banding model of right ventricular hypertrophy showed that transgenic expression of Bmpr2 R899X in the heart, expressed as a truncated protein and hence not subject to NMD, results in reduced right ventricular remodeling associated with intracardiomyocyte lipid deposition 43 . It is noteworthy that aged Bmpr2 +/R899X mice are susceptible to PAH, whereas Bmpr2 heterozygous-null mice are not 27 . There is no clear explanation for this observation, since both would be expected to result in haploinsufficiency. It remains possible that incomplete NMD of the mutant transcript in Bmpr2 +/R899X mice plays a role, although we do not have evidence for this.
The potential of BMP9 as a therapeutic agent for PAH is highlighted by its efficacy in reversing established disease in three animal models of PAH, given that any viable treatment will need to be effective in a patient population that typically presents with advanced disease. The ability of BMP9 to reverse disease in the Sugen-hypoxia rat model is a particularly important indicator of the potential application of this treatment strategy to the clinic, as this is the only disease model that recapitulates the intimal lesions and advanced vascular remodeling observed in individuals with PAH. In these disease models, as in cultured endothelial cells, BMP9 promotes vascular stability by simultaneously preventing apoptosis and blocking pathological angioproliferation. Our observation of increased endothelial apoptosis at later timepoints in both the MCT and Sugen-hypoxia rat models supports the suggestion that endothelial apoptosis is not only a driving factor in disease onset, but an ongoing phenomenon in established disease occurring concurrently with pathological angioproliferation. This concept is supported by our observation that BOECs from BMPR2 mutation-bearing individuals with established PAH are more susceptible to apoptotic stimuli as compared to BOECs from control subjects.
Our work provides proof of concept for the treatment of PAH through the direct enhancement of endothelial BMPR-II signaling using recombinant BMP9 protein. BMP9 not only protects pulmonary arterial endothelial cells from apoptosis and promotes vascular stability, but also increases BMPR2 gene expression, allowing for further enhancement of BMPR-II signaling. These effects were observed even in cells derived from individuals bearing mutations in BMPR2, suggesting that this treatment might be efficacious in PAH patients with or without BMPR2 mutations. Taken together, our findings suggest that approaches based on targeting the canonical endothelial BMPR-II-ALK-1 complex using recombinant ligands or small-molecule receptor agonists may provide a promising new approach for the treatment of PAH.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Cell culture. Human pulmonary artery endothelial cells (PAECs), human umbilical vein endothelial cells (HUVECs) and human aortic endothelial cells (HAECs) were purchased from Lonza (Basel, Switzerland). PAECs, HUVECs and HAECs were cultured in EGM-2 with 2% FBS (Lonza), as per the supplier's instructions. HMEC-1 cells were obtained from the Centers for Disease Control and Prevention (CDC, Atlanta, GA) and cultured in MDCB131 (Invitrogen) containing 10% FBS, 10 mM l-glutamine (Sigma), 1 µg/ml hydrocortisone (Sigma) and 10 ng/ml human epidermal growth factor (Sigma). Human BOECs were generated from 40-80 ml peripheral blood and characterized as described previously 44 . PAECs were characterized similarly. BOECs were cultured in EGM-2MV with 10% standard grade FBS (Life Technologies, Carlsbad, CA) and were used for experiments between passages 4 and 8. Unless specified otherwise, treatment of human endothelial cells with BMPs was performed in EBM-2 (Lonza) with 0.1% FBS.
The endothelial nature of BOECs was assessed by flow cytometry for endothelial surface marker expression as described previously 44 . All cell lines were routinely tested for mycoplasma contamination. For experiments involving BOEC generation, all blood donors provided informed consent in accordance with human study 07/H0306/134 (Cambridgeshire 3 Research Ethics Committee). Information on the specific BMPR2 mutations present in BOECs is specified in Supplementary Table 2 .
Mouse lung microvascular endothelial cells were isolated as described previously 45 with minor modifications. Briefly, minced lung tissue was digested for 30 min at 37 °C in 2 mg/ml collagenase I (#C1639, Sigma-Aldrich, St. Louis, MO), dissolved in DPBS with calcium and magnesium and filtered through a 70 µm cell strainer. The resultant cell suspension was incubated for 10 min at room temperature with sheep anti-rat IgG Dynabeads (#11035, Life Technologies), preconjugated with rat anti-mouse PECAM-1 (#550274, BD Biosciences, Franklin Lakes, NJ). Magnetically isolated cells were washed multiple times in DMEM and plated on tissue culture plates precoated with 0.1% gelatin (Sigma) for 24 h in Endothelial Growth Medium, consisting of DMEM with 20% FBS, 1× penicillin-streptomycin-glutamine (Life Technologies), 0.1 mg/ml heparin (Sigma) and 0.1 mg/ml endothelial cell growth factor (Biomed Tech Inc., Ward Hill, MA). After 24 h, cultures were washed to remove nonadherent cells and allowed to grow for 5-9 d until near confluency. Cells were then trypsinized and endothelial cells were purified by a second round of positive magnetic selection with Dynabeads. Resultant endothelial cells, which grow with typical cobblestone morphology, were then replated on gelatin-coated plates in Endothelial Growth Medium.
Human and mouse PASMCs were isolated and cultured as described previously 46 . Unless specified otherwise, treatment of PASMCs with BMPs was performed in DMEM with 0.1% FBS.
Microarrays. PAECs (n = 4) or BOECs (n = 3) from healthy subjects were quiesced in M199 media with 0.1% FBS for 12 h before a 4 h stimulation in new media with vehicle, 1 ng/ml BMP9, 10 ng/ml BMP2 or 10 ng/ml BMP6 (all from R&D Systems, Minneapolis, MN). Cell monolayers were lysed in TRIzol (Life Technologies) and purified mRNA was hybridized to Human Genome U133 Plus 2.0 GeneChips (Affymetrix, Santa Clara, CA). Quality control, background correction and normalization were performed using R/Bioconductor (http://bioconductor.org). Differential gene expression was assessed by fitting linear models and the resulting P values were adjusted for multiple testing 47 . Enrichment of gene-sets was determined using Generally applicable geneset enrichment (GAGE) 48 and signaling pathway impact analysis (SPIA) 49 . Pathway diagrams were generated with the Pathviews package 50 . The pathway maps of interest, i.e. "Environmental Information Processing" and "Cellular Processes, " were retrieved from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Microarray data are available in the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-2495). siRNA knockdown and qPCR. Cells were maintained in Optimem serumfree medium (Life Technologies) for 3 h before the addition of Dharmafect 1 transfection reagent with or without siRNAs for Smad1, Smad5 or BMPR2 or a control pool of oligonucleotides (all Thermo Fisher, Waltham, MA) for 4 h. After siRNA treatment, cells were returned to culture media for 24 h before use. qPCR for Smad1, Smad5, BMPR2 and VEGFA mRNA was performed as described previously 30 and presented relative to GAPDH, β-2 microglobulin, HPRT, β-actin or a combination of these housekeeping genes.
Immunoblotting. After the indicated duration of treatment, cells were lysed in phosphate-buffered saline (PBS) containing 50 mM Tris pH 8.0, 1% Igepal, 0.1% SDS, 0.5% sodium deoxycholate and Roche cOmplete protease inhibitor cocktail (Roche, Basel, Switzerland). Lysates were sonicated and frozen at −80 °C until used. Cell lysates (20-40 µg total protein) were separated on reducing SDS-PAGE gels and proteins were transferred to polyvinylidene fluoride membranes by semidry blotting. Membranes were then blocked and probed with rabbit polyclonal antibodies toward JNK (#9252), phospho-JNK (#9251), Smad1 (#9743), phospho-Smad1/5/8 (#9511, all Cell Signaling Technology, Danvers, MA) or PCNA (#ab18197, Abcam, Cambridge, UK); rabbit monoclonal antibodies toward caspase-3 (clone 8G10), cleaved caspase-3 (clone 5A1E), phosphorylated Smad1/5 (clone 41D10, all Cell Signaling Technology, Danvers, MA), Smad5 (clone EP619Y, Epitomics, Burlingame, CA), Id1 (clone 195-14) or Id3 (clone 17-3, both CalBioreagents, San Mateo, CA); or a mouse monoclonal antibody toward BMPR-II (clone 18/BMPR-II, BD Transduction Laboratories, Franklin Lakes, NJ). As a loading control, all blots were reprobed with a monoclonal antibody toward either α-tubulin (clone DM1A, Sigma) or β-actin (clone AC-15, Sigma). Densitometry was performed using ImageJ software.
Chromatin immunoprecipitation (ChIP). ChIP assays were performed using a chromatin immunoprecipitation assay kit (EMD Millipore, Billerica, MA) in accordance with the manufacturer's instructions. HMEC-1 cells at 80-90% confluency were assayed either at baseline, 72 h after siRNA knockdown of Smad1 or following a 24 h stimulation with 1 ng/ml BMP9 (R&D Systems). Cells were cross-linked with 1% formaldehyde for 10 min at 37 °C. 125 mM glycine was added to block cross-linking. Cells were then rinsed with PBS and lysed in 200 µl buffer containing 1 µg/ml aprotinin, pepstatin and 1 mM phenylmethylsulfonyl fluoride. Chromatin samples were sonicated with 4 sets of 10-s pulses on wet ice using a Cole Parmer, High Intensity Ultrasonic Processor/Sonicater, 50-W model equipped with a 2 mm tip and set to 30% maximum power to fragment the DNA to lengths between 200 and 1,000 bp. The sonicated lysate was then diluted to 2 ml with dilution buffer containing a protease inhibitor cocktail. After preclearing with salmon sperm DNA-Protein A-agarose for 1 h at 4 °C, 20 µl (1%) of this solution was removed as 'input' for PCR analysis. 2 µg of the immunoprecipitating antibodies for phospho-Smad1/5 or Smad4 (#9516 and 9515, respectively, Cell Signaling Technology) were added to the remaining sample (for the negative control, rabbit polyclonal IgG (#I5006, Sigma) was added), and the sonicated lysates were incubated overnight at 4 °C. Immune complexes were collected with 60 µl of salmon sperm DNA-Protein A-agarose (1 h at 4 °C), and agarose beads were washed with solutions of increasing ionic strength. After a final wash, bound immune complexes were eluted in a freshly prepared solution of 1% SDS and 0.1 M NaHCO 3 , and the cross-links were reversed in the samples (and the input from the sonicated lysates) by heating at 65 °C overnight. Samples were then treated with proteinase K, and DNA was phenol-chloroform-extracted and precipitated. DNA was resuspended in 20 µl H 2 O, and 1 µl was used for detection of the BMPR2 promoter by PCR using the oligonucleotides 5′-GAACACATCAAAGGGGTGGT-3′ and 5′-GTGGCCTTTCTCCTTCACAC-3′, which together amplify 350 bp spanning from −1797 to −1448 of the promoter region. DNA from the input was resuspended in 20 µl, and 1 µl was used for PCR. BMPR2 promoter constructs. A 5-kb fragment of the human BMPR2 promoter was generated by polymerase chain reaction (PCR) from BAC clone RP11-68606. A 5′ primer (5′-GCGCGAGCTCTAGTCCTCCCTGCCCCTTAT-3′), including a SacI site for subcloning, and a 3′ primer (5′-GCGCAAGCTTAGCAGGATGG TCCATGGTAG-3′), initiating 59 bp upstream of the transcription start site and containing a HindIII site, were used. The amplified product was purified and cloned into the SacI-HindIII-digested promoter-deficient reporter vector pGL3basic (Promega, Madison, WI) to give the BMPR2-luc construct. The putative Smad binding site in the BMPR2 promoter was mutated using the PCR-based QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) and the following primers: Fwd, 5′-GCTCTGCACCACAGGCTAGAGtgAtcCAGGGCC npg
